Cerebrovascular and cardiovascular disease burden in patients with hereditary hemorrhagic telangiectasia.

Introduction: Hereditary hemorrhagic telangiectasia (HHT) is a rare genetic disease with prevalence of approximately 1 in 5000–10,000. We evaluated the prevalence and association of cerebrovascular and cardiovascular comorbidities in HHT patients using national database. Methods: Retrospective observational study was performed using National Inpatient Sampling (NIS) database for the year 2014. HHT patients and comorbidities were identified using ICD-9 codes. Univariate and multivariate analyses were performed using SAS. Results: Prevalence of HHT was 0.0119% with predominance in White population. Mean age of HHT patients was 59 years. Increased proportion of HHT patients had hypertension (46.8% vs 42%), anemia (28.9% vs 15.1%), chronic pulmonary disease (24.8% vs 16.4%), congestive heart failure (15.7% vs 7.5%), liver disease (7.9% vs 2.8%), migraine (4.5% vs 1.5%), and cerebrovascular malformations (0.8% vs 0.03%), whereas chronic kidney disease (12.7% vs 12.2%), headaches (1.3% vs 1.1%), seizures (0.7% vs 0.9%), transient ischemic attacks (1.06% vs 1.03%), ischemic (1.2% vs 1.0%), and hemorrhagic (0.5% vs 0.3%) strokes were similar to those without HHT. Multivariable model shows increase in cerebrovascular malformations (OR 11.04, CI 2.49–22.26, p < 0.0001), migraine (OR 3.23, CI 2.30–4.52, p < 0.0001), chronic blood loss anemia (OR 6.83, CI 5.36–8.71, p < 0.0001), congestive heart failure (OR 1.55, CI 1.26–1.91, p < 0.0001), chronic pulmonary disease (OR 1.30, CI 1.09–1.56, p = 0.0038), and hepatic disease (OR 2.63, CI 2.01–3.45, p < 0.0001) in HHT patients as compared to non-HHT patients. Conclusion: There is a need for a large prospective registry of HHT patients that can corroborate these associations and burden of cerebrovascular and cardiovascular diseases. [ABSTRACT FROM AUTHOR]